Göktürk Han Doğan

Dr. Göktürk Han Doğan

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GDGöktürk Han Doğan
Göktürk Han Doğan
CSCeren Sağlam
Ceren Sağlam
İGİbrahim Gülhan
İbrahim Gülhan
IAIlayda Gercik Arzik
Ilayda Gercik Arzik
AİAbdurrahman hamdi İnan
Abdurrahman hamdi İnan
YPYunus Emre Purut
Yunus Emre Purut
Background/Objectives: The prevalence of Human Papilloma Virus (HPV) in Türkiye may vary from that reported in other countries. Determining the age-specific distribution of HPV infection and its overall prevalence in all tested individuals, supported by a large sample size, would provide valuable insights for HPV prevention programs. This study aims to determine the regional prevalence of HPV infection. Methods: This is a retrospective study containing data from 52,930 patients who underwent HPV testing at a tertiary hospital between 2016 and 2024. Patients aged 21 to 65 were included in the study. Target DNA amplification by polymerase chain reaction (PCR) and nucleic acid hybridization techniques were performed for the identification of HPV. Overall prevalence, age-specific prevalence, and genotype distribution were examined. Results: Analysis of genotype distribution revealed that isolated HPV16 positivity was 4.0% (n = 2118), isolated HPV18 positivity was 1.0% (n = 528), and isolated other high-risk (HR) HPV types (excluding HPV16 and HPV18) were detected in 10.8% (n = 5693) of patients. The co-positivity rates were as follows: HPV16 and HPV18 in 0.4% (n = 237), HPV16 and HR-HPV other in 2.3% (n = 1197), HPV18 and HR-HPV other in 1.0% (n = 513), and HPV16, HPV18, and HR-HPV other in 0.3% (n = 145). Conclusions: This study highlights that HPV positivity is higher among individuals aged 21–24 years in our population, the overall prevalence is broadly consistent with the range reported in previous Turkish and international studies, and the pooled other HR-HPV group was more frequent than HPV16 or HPV18 individually.

5 October 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
GDGöktürk Han Doğan
Göktürk Han Doğan
GAGöksever Akpınar
Göksever Akpınar
ATAnıl Doğukan Tutal
Anıl Doğukan Tutal
CSCeren Sağlam
Ceren Sağlam
AAAyşe Berin Acar
Ayşe Berin Acar
YPYunus Emre Purut
Yunus Emre Purut
Background/Objectives: Bowel resection is often required for complete cytoreduction in advanced ovarian cancer, and some units perform upper gastrointestinal endoscopy and colonoscopy beforehand. We compared the endoscopic biopsy findings with the histopathology of the resected bowel and examined determinants of survival. Methods: Eighty-three consecutive women with FIGO stage III–IV serous ovarian cancer cytoreduced to no macroscopic residual disease between 2015 and 2021 were reviewed retrospectively; all had undergone both examinations and completed adjuvant carboplatin–paclitaxel. Results: Bowel resection was performed in 20 women (24.1%). Serosal involvement was reported in 15 specimens and no tumour in four; mucosal invasion was reported in none (95% CI 0–16.8%). Eighteen patients (21.7%) were biopsied endoscopically; no biopsy was malignant. Over a median follow-up of 72 months, 50 women (60.2%) developed recurrence (28 confirmed histologically and 22 diagnosed from imaging and CA-125; recurrence was ascertained retrospectively, which limits the interpretation of disease-free survival) and 44 (53.0%) died. Recurrence was no more frequent in biopsied than in non-biopsied patients (8/18 vs. 42/65, p = 0.174) or after resection (10/20 vs. 40/63, p = 0.306). Age showed an exploratory association with disease-free (HR 1.03/year, 95% CI 1.00–1.06) and overall survival (HR 1.04, 1.00–1.07). Conclusions: In this cohort, no preoperative endoscopic biopsy was malignant and no resected specimen was reported to show mucosal invasion, supporting a limited role for routine endoscopy in assessing bowel wall involvement; its diagnostic accuracy and its value for excluding a gastrointestinal primary could not be assessed.

18 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SSSerhat Sarıkaya
Serhat Sarıkaya
YPYunus Emre Purut
Yunus Emre Purut
ATAnıl Doğukan Tutal
Anıl Doğukan Tutal
CSCeren Sağlam
Ceren Sağlam
GDGöktürk Han Doğan
Göktürk Han Doğan
ABAdnan Budak
Adnan Budak
Background/Objectives: Vaginal natural orifice transluminal endoscopic surgery lateral suspension (vNOTES-LS) may reduce the perioperative burden of conventional laparoscopic lateral suspension (LLS), but comparative evidence remains limited. We compared perioperative, anatomical, safety, and patient-reported outcomes. Methods: This single-center retrospective cohort included 97 women with stage III–IV pelvic organ prolapse who underwent vNOTES-LS (n = 33) or LLS (n = 64) and completed 12-month follow-up. The primary outcome was anatomical success at 12 months. Results: Operating time was shorter with vNOTES-LS (78.0 ± 16.6 vs. 110.0 ± 14.2 min; p < 0.001), as were estimated blood loss, hospitalization, and 24-h pain scores. After adjustment, vNOTES-LS was associated with a 31.7-min shorter operating time (95% CI, −38.7 to −24.6; p < 0.001). Anatomical success was 87.9% versus 89.1% (p = 1.000; RR, 0.99; 95% CI, 0.85–1.15), with an absolute risk difference of −1.2 percentage points (95% CI, −14.7 to 12.3). Cumulative mesh exposure within 12 months was 9.1% and 9.4%, respectively. No statistically significant between-group differences were detected in recurrence, measured safety outcomes, or longitudinal changes in the Pelvic Floor Distress Inventory-20 (PFDI-20), Pelvic Floor Impact Questionnaire-7 (PFIQ-7), and 12-item Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). Conclusions: vNOTES-LS was associated with shorter operating time and favorable early perioperative outcomes. Observed 12-month anatomical success rates were not statistically significantly different; however, equivalence or non-inferiority cannot be concluded.

4 November 2026 in Medicina
Verified
Journal Article
Open access
PDF file
ATAnıl Doğukan Tutal
Anıl Doğukan Tutal
YPYunus Emre Purut
Yunus Emre Purut
GDGöktürk Han Doğan
Göktürk Han Doğan
SSSerhat Sarıkaya
Serhat Sarıkaya
CSCeren Sağlam
Ceren Sağlam
MSMUZAFFER SANCI
MUZAFFER SANCI
Background and Objectives: Histological subtype in epithelial ovarian cancer determines chemosensitivity and prognosis but is usually confirmed only on the surgical specimen. We asked whether any preoperative serum tumour marker, or any ratio between two, is associated with non-serous histology and adds to International Federation of Gynecology and Obstetrics (FIGO) stage. Materials and Methods: Retrospective cohort of 157 women operated on for epithelial ovarian cancer in 2016–2024 with complete chemotherapy-naive CA125, carcinoembryonic antigen (CEA), CA19-9 and CA15-3 values (pre-cycle-one values in 64 neoadjuvant patients). Four markers and six pairwise ratios were assessed by Mann–Whitney tests with Benjamini–Hochberg correction, receiver-operating-characteristic analysis and Firth penalised regression; discrimination was internally validated by bootstrap resampling that repeated the selection of the leading index. Results: Twenty-four tumours (15.3%) were non-serous. The CA125/CA19-9 ratio ranked first (area under the curve 0.796, 95% confidence interval 0.696–0.883) but was not superior to CA125 alone (0.708; p = 0.072), and stage alone performed comparably (0.805). Adding the ratio to stage improved fit (p = 0.001; odds ratio 0.36 per ten-fold increase, 0.17–0.71; selection-adjusted permutation p = 0.021). Optimism-corrected areas were 0.766 for the ratio alone and 0.869 for stage plus ratio; CA15-3/CA19-9 and CA19-9 alone added to stage similarly. The threshold of 12.2 was unstable (bootstrap range 2.6–58.7) and discrimination was 0.575 in early-stage disease. Raised CA19-9 arose from clear cell (p = 0.002) and mucinous (p = 0.022) but not endometrioid tumours (p = 0.92). Conclusions: CA19-9 carries histotype information beyond CA125 and stage, arising from clear cell and mucinous tumours, whether expressed alone or as a ratio; neither is usable as a stand-alone preoperative test or to guide treatment. The finding is hypothesis-generating and requires external validation alongside human epididymis protein 4 (HE4) and the Risk of Ovarian Malignancy Algorithm (ROMA).